Effect of intraoperative radiotherapy in the treatment of retroperitoneal sarcoma

Abstract

IORT was used infrequently for RPS but generated equivalent outcomes compared to EBRT, despite being utilized more often for larger tumors and those with peri-tumoral soft-tissue invasion. Patients with the most common subtype (liposarcoma) may benefit from combination IORT with adjuvant EBRT versus other regimens.

Intraoperative radiation therapy in non-breast cancer patients: A report of 26 cases from Shiraz, south of Iran

“…Retroperitoneal sarcoma does not have a good prognosis. In studies, 5 year local control is 50% and 10 year survival is about 5% (11,12).…”

A systematic review of population-based studies examining outcomes in primary retroperitoneal sarcoma surgery

“…Of the 14 included studies reporting on 3 nationally recognised central databases, one was from Canada and the USA 25 and the others were all from the USA [26][27][28][29][30][31][32][33][34][35][36][37][38] (Table 1). Six studies used The Surveillance, Epidemiology and End Results (SEER) database [25][26][27][28][29][30], five studies reported from the United States National Cancer Data Base (US NCDB) [31][32][33][34][35] and the final three used the American College of Surgeons' National Surgical Quality Improvement Program (ACS NSQIP) [36][37][38]. The 14 studies span over four decades of surgical treatment for retroperitoneal sarcomas, with the earliest studies reporting data from 1973 [25,28] and the most recent from 2015 [31].…”

“…Studies from the SEER and US NCDB databases did not report 30-day morbidity rates [25][26][27][28][29][30][31][32][33][34][35]. However, Ecker et al did report a hospital readmission rate within 30-days of 6.9% for the neo-adjuvant radiotherapy group (12/174 patients) and 6.3% for the surgery alone group (120/1 908 patients), with no statistical difference [32].…”

“…Significant predictors of mortality on multivariate analysis were male gender (OR 0.11; 95% CI 0.01-0.93; p=0.04) and impaired functional status (OR 44.17; 95% CI 5.65-345.20; p<0.0001) [38]. Studies from the SEER database did not report 30-day mortality rates [25][26][27][28][29][30].…”

“…No studies across the three population-based databases reported loco-regional recurrence rates [25][26][27][28][29][30][31][32][33][34][35][36][37][38].…”